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Some ethical reflections on weight-loss diets
Hakan ERTİN, Bülent ÖZALTAY

Aim: To assess how weight-loss diets tend to move away from the authority of conventional medicine and become a field
of abuse. Endocrinologists and specialists on metabolic diseases are rarely called upon to speak about obesity, whereas
physicians from unrelated fields or nonphysicians frequently appear in the media.
Materials and methods: The literature related with the field was reviewed and interpreted from an ethical perspective.
Results: It is presented medically doubtful solutions via television and the internet. Several weight-loss drugs are
introduced to the market without adequate controls and then have to be withdrawn after having caused serious damage
to the health of a significant number of users – and after producing large profits for the providers.
Conclusion: The main purpose is actually gaining money or popularity rather than curing people’s weight problems.
Attitudes, which are far from conforming to human responsibility and the ethical principle of not causing harm, are
tainting the reputation of pharmacology. In order to overcome such sort of abuses, the authority of conventional medicine
should be emphasized, drug production should be carefully controlled, and misinformation dealt out by non-specialists’
advices and the unqualified promotion of herbal recipes through media communication should be prevented.
Key words: Commercial medicine, medical ethics and diet, weight-loss diets and medical ethics, endocrinology
metabolism and medical ethics, weight-loss industry, weight-loss drugs

Kilo verme diyetleri hakkında bazı etik düşünceler
Amaç: Endokrinoloji ve metabolizma hastalıkları uzmanlarına obezite konusunda nadiren söz verilirken, ilgisiz
branşlardan hekimler ya da hekim dahi olmayan kimseler sık sık medyada yer almaktadır. Bu çalışmanın amacı, kilo
verme diyetlerinin klasik tıbbın hakimiyetinden çıkıp bir suistimal alanı haline gelişini irdelemektir.
Yöntem ve gereç: Konu ile ilgili literatür taranarak, elde edilen bilgiler etik perspektiften yorumlanmıştır.
Bulgular: Kilo verme diyetleri ile ilgili olarak, televizyon ve internet aracılığı ile tıbbi dayanağı şüpheli çözümler
sunulmaktadırlar. Çeşitli zayıflama ilaçları yeterince tetkik edilmeden kolayca piyasaya sürülmekte; ciddi sayıda insanı
sıhhen olumsuz etkiledikten – ve kar edildikten – sonra geri çekilmektedir.
Sonuç: Kilo verme diyetlerinde genel olarak para ya da popülarite hedeflenmektedir. İnsani sorumluluktan uzak, zarar
vermeme ilkesine kayıtsız bu gibi tutumlar farmakolojiyi lekelemektedir. Söz konusu suistimallerin üstesinden gelmek
için, geleneksel tıbbın otoritesi vurgulanmalı, ilaç üretimi daha hassas bir kontrole tabi tutulmalı; özel ihtisası olmayan
kişilerin, bitkisel reçete ve tavsiyelerinin, iletişim organları kanalıyla yarattığı bilgi kirliliği önlenmelidir.
Anahtar sözcükler: Ticari tıp, tıp etiği ve diyet, kilo verme diyetleri ve tıp etiği, endokrinoloji-metabolizma ve tıp etiği,
kilo verme endüstrisi, kilo verme ilaçları
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Introduction
When the World Health Organization published
a declaration on obesity in 1977, considering it a
serious condition affecting human health, those
foreseeing its importance in the not-so-distant future
were surely a minority (1). The topic, which is covered
under different labels, including overweight-dietingobesity, and which could be called ‘weight problems’
in general, is a concern of the greatest prevalence at
the present day.
However, there is a difference that distinguishes
the story of these weight problems from other
concerns. When addressing this issue, is it possible
for us to speak of a process free from nonmedical
interference, in which diagnosis and treatment are
defined by accurate and objective experience and
medical expertise, adhered to as in other health
conditions?
Dieting, which used to be a medical matter, seems
to have become a part of daily life as an unquestioned
and ordinary rule, especially among women, posted
on almost every refrigerator today. Formerly, specific
diets as a part of the regular treatment of a main
disease, with which patients hence had to comply,
were prevalent mostly among the middle-aged and
elderly. However, a necessity has recently emerged to
classify diets as either medical or popular, for the issue
has long since gotten out of the control of the medical
world. While special diets related to such disorders
as hypertension, diabetes, and high blood cholesterol
or slimming programs aimed at reducing detrimental
weight burdens used to constitute a majority of all
dieting, popular diets undertaken by people from all
age groups out of aesthetic concerns present a greater
percentage now. The main reason behind this trend is
that, since overweight was first declared a disease, it
has gone beyond this initial status: it is now perceived
as a visual disaster, an unacceptable case regardless of
what causes it or how much extra weight is really in
question.
Reflections on commercial medicine: how and
why to lose weight
The concern caused by excess weight has increased
in parallel with a change in certain concepts. While
in the 1950s women with a regular weight, neither
too fat nor too slim, were appreciated in many
952

Western countries, a teenage girl in London, Twiggy,
was ‘discovered’ as a fashion model in the 1960s;
the powers behind the discovery quickly agreed
about the innocent appearance and extraordinary
beauty of this girl, who could never have achieved
such fame even a few years earlier. The first reaction
of the fashion world upon seeing Twiggy was not
admiration, but rather surprise. However, as they
realized that this girl, who was about three-fourths
the weight of the usual models of the time, promised
a new trend and a new production-consumption
wave, or, in other words, revenues, she was accepted
and made acceptable. She was introduced to the
world in magazines as the new fashion. Her body,
much thinner than the prevailing norm, displayed
clothes especially designed for it, while her large eyes
promoted a number of cosmetic products; movies
of the period also reflected this trend. Shortly after
the death of American Marilyn Monroe, who left
her mark on the century with a normal weight and
idealized the blonde and attractive woman through
the 1950s, the standard was taken over by the British
Twiggy. Regular sizes were now outmoded, whereas
the very thin – and somewhat sad – woman was
beautiful. In time, this became the new appearance
expected from women.
Of course, 16-year-old Twiggy, who weighed 40 kg
at a height of 1.70 m, could not make it on her own; the
media, whose great power was then widely utilized,
served in the same direction. There was a message
pushed by all media channels, from television to
newspaper supplements: the thin woman is beautiful.
Furthermore, according to the idealization imposed,
the thinner this woman gets, the more beautiful she
becomes. Every image and each product on display
invited women to lose weight, and they were not
indifferent to it.
As one actual marker, the current high incidence
of bulimia nervosa, formally described only in 1979,
is noticeable, particularly in female high school or
college students (2). The media has played a large role
in the rise of bulimia nervosa, previously thought to
be related only to white women and characterized
by periods of binge eating followed by defensive
vomiting and engagement in long-term fasting,
laxative use, and/or overexercise (3-5). A survey
conducted shortly after the introduction of television
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to Nadroga, Fiji, demonstrated that the incidence of
bulimic vomiting among high school girls around 17
years old was 0% in 1995; after 3 years of exposure
to television, it reached 11.3% in 1998 (6). Likewise,
another analysis indicated that both EuropeanAustralian girls and Fijian girls aged between 13
and 18 years, despite the latter group’s sociocultural
values promoting a larger body, are both inclined
to stay thin and are worried about weight gain
because of concerns about their physical appearance
(7). When we look at Asia, we see that body-image
disorders and physical dissatisfaction are on the rise
there, too; a study performed with 517 adolescents in
China stated that, beside females reporting a greater
physical dissatisfaction than males, females feel
pressure from the media to lose weight, while males
are held by various sociocultural sources to increase
their muscle mass (8). A study among 336 female
college students in Taiwan reported that unhealthy
dietary behaviors have become prevalent; 67.6% of
the students had lost weight, 51% had dieted at least
once to lose weight, and 17.9% applied for weightloss medication (9). Such significant findings are not
limited to those who might be regarded as young girls
lacking in medical awareness; the increase in eating
disorders and psychological problems related to the
unrealistic perception of the body can be found in all
environments. We more often mention the condition
of anorexia nervosa, characterized by a perpetual
complaint of overweight despite the actual presence
of extreme underweight, leading sufferers to restrict
nutrition and producing the highest mortality
among all psychiatric illnesses (10,11). A female
adolescent not influenced by the thin ideal represents
a remarkable rarity in our time.
However, besides the fact that such disorders
do not receive enough attention, many members
of the medical profession are accomplices in the
obesity-dieting dilemma. Some of them routinely
go public with various forms of advice and dietary
suggestions despite the fact that their specialty is
not in endocrinology or metabolism. Nonspecialist
and nonpersonalized advice from outside or
generalized treatments disregarding patients’
personal backgrounds are all threats to health. At
this point, we should pose the crucial question: What
kind of solution is offered for women trying to lose
weight? The answer may point to the mechanism and

circumstances of the ‘thin’ fashion since the 1960s.
As obesity turned into a most worrying disease,
when even a few extra pounds were perceived as a
serious disadvantage, the backstage players of the
health care sector – some pharmaceutical companies
– went into action. As almost no products had been
available in this field until the 1930s, dinitrophenol
(2.4-DNP), which had been used as an herbicide and
fungicide and was known to induce weight loss by
increasing metabolism, was introduced to the market
in this period (12,13). The use of DNP, which stood
on a thin line between disputable therapeutic benefit
and definite toxicity, was terminated in 1938 due
to its numerous side effects, ranging from cataracts
and hyperemia to hyperthermia and hyperpyrexia
(13,14). However, by that time, during the first 15
months following the introduction of the drug,
100,000 people had taken this potentially lethal
medicine in order to lose weight, which was sold with
no further directions other than “3 times daily after
meals” (15).
In the 1950s, the decade after the ban of DNP,
the production of weight-loss drugs accelerated.
Amphetamine used to keep soldiers awake and
alert during World War II and was subsequently
used in medicine, sometimes as an antidepressant,
sometimes as a means for weight reduction, and even
as a decongestant. It became a main weight-loss drug
during the 1950s and its use continued until the late
1960s (16,17). It may seem a strange coincidence that
some drug producers were searching for new weightloss medicines right before the onset of the slimming
wave triggered by Twiggy only a few years later.
Although amphetamine, too, was gradually
abandoned due to its side effects and addiction due
to improper use, the introduction of new drugs never
ceased. Phentermine was approved by FDA as a new
remedy in 1959, and fenfluramine (Pondimin) was
introduced in 1973 (18). Fenfluramine was withdrawn
from the market in the USA in 1997 for its serious
danger of producing problems such as heart valvular
damage, but it should be noted that 18 million
prescriptions had been written for fenfluramine and
phentermine (19,20). Another slimming drug was
dexfenfluramine (Redux), approved in 1996 and also
withdrawn in 1997 along with fenfluramine because
of its negative effects on health (18,21).
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In the very same year, 1997, the FDA approved
sibutramine (Meridia) as the successor of Redux and
Pondimin; 2 years later, in 1999, orlistat (Xenical) was
licensed (22,23). While in the US orlistat now stands
accused of provoking severe liver damage, the latest
drug investigated in Turkey has been Lida, imported
from China. The sale of Lida, claimed to induce
death by liver and renal failure, was terminated by
the Ministry of Health (24). On the other hand,
many drug users think they are safe; a study showed
that 64% of weight-loss drug users believe that the
government requires warnings about potential side
effects, 54% believe that products are approved by
the FDA for safety, and 46% think they are approved
for efficacy – and, actually, these beliefs are all wrong
(25).
The uncontrolled trials of firms designing weightloss drugs unsuccessfully continue, creating further
health damage, including death. But why are these
companies so persistent despite so much failure?
Aside from these drugs, the ‘weight-loss
industry’ has reached an enormous volume with its
subdivisions such as diet programs, diet products,
and exercise. The American slimming market, which
had a turnover of $35 billion in 2000, had $55 billion
spent on it in 2006; the 2009 GDP of the European
country of Luxembourg was $52 billion (26-28).
The ‘customers’ spent almost $1 billion each year on
products that are at best safe enough not to damage
health, but unproven (25).
In contrast to the generous opportunities offered
to investors, there hardly seems to be a similar benefit
for the customer. Globally, from the developed
countries, and particularly in the US where weightloss products are most in demand, to the developing
world, the number of overweight people is on the
rise (29). The American obesity incidence of 13%
among adults in the 1960s is expected to reach
41% in 2015; among children, the prevalence of
overweight has already increased from 1999 to
2004, and since healthy nourishment is replaced by
affordable energy-dense but nutrient-poor foods, the
rate increases as income level drops (30-32). While
the producers back up their claims with healthy
and slim smiles telling success stories, many studies
indicate that weight-loss drugs and ‘wonder diets’ are
useless. It is known that almost 80% of the product
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users’ efforts fail, which is to say that the mediocre
weight loss of 5% to 10% obtained on average with
these drugs is not maintained and eventually the
previous weight is regained (33-37). In other words,
before prescribing a weight-loss drug that promises
a weight loss of 10% at best with a 20% chance of a
lasting result, a responsible physician must make a
serious risk-benefit analysis: primum nil nocere, the
main medical ethics principle of “first, do no harm.”
On the other hand, similar to the standardization
of the human body and that of women in particular,
many concepts referring to health have been
commercialized. The consequences of the free and
fast lifestyle of the 1980s, with careless consumption
of refined sugar, fat, and fast food as another freedom,
are considered to be among the major reasons of the
present obesity rate, but those were all popular at that
time, in contrast with the ‘thin beauty’ simultaneously
prevailing in the media. Fast food, which is now a
saturated sector after profiting at levels of billions of
dollars, has recently been supplanted by the idea of
‘back to nature,’ sold under the name ‘organic farming’
with a growing demand. Organic farming, which was
the only farming our ancestors knew, and natural
nutrition have regained currency after the experience
of the downside of industrial and modern trends, but
their products have returned to the shelves at much
higher prices. In addition, various food fashions keep
arising. Sushi from Japanese cuisine, far from being
the perfect food with the raw fish that it contains and
a risk of high levels of mercury intake or parasitic
infection, has become a worldwide health symbol
(38,39). After a long time on the blacklist, butter
and eggs have newly been announced as safe. Coffee,
which has always been an ordinary beverage with
a controversial balance of pros and cons, has been
bestowed with an eminent status.
Although obesity is a health condition, medical
experts have lost their leading role in decisions about
who should lose how much weight by what means. In
accordance with the changing eating trends, people
are constantly informed about what kind of food can
be deemed healthy and help them to stay slim, but
the qualifications of those guides are often dubious.
A number of private dieticians under no medical
control, sports trainers, and herbalists with previous
experience of prescribing in this direction seem to
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be the new protagonists of the overweight problem.
While these unauthorized actors easily reach the stage,
scientific authorities in the field are rarely offered the
same opportunity. The numerous teas, herbal recipes,
and mixtures alleged to ensure weight loss that have
lately become so prominent on Turkish televisions
could be nothing but quackery. It is clear that people
appearing in audiovisual and printed media are
not endocrinology and metabolism specialists, but
either just general practitioners or physicians from
unrelated branches; in most cases, they are not even
physicians. As a result, the increasing prevalence of
obesity benefits many groups financially. A positive
effect of the disinformation may at least be the
increased public awareness of obesity and health; on
the other hand, we might wonder how the generations
of 30 years ago, without so much guidance, could lead
healthier and ‘lighter’ lives than do people of our day.
As for the medical mindset today, it may not
generally object to the exploitation of certain
disorders. The seriousness and priority of health
problems in modern medicine are uncertain and
disease definitions are more ambiguous than ever
before; diseases have been commercialized. While the
notion of ‘patient’ is replaced with that of ‘customer,’
the relevance of some diseases is exaggerated,
new ones are invented, and more and more people
are categorized as patients – or as customers, for
that matter (40). Advertising and drug companies
work hand-in-hand to medicalize new conditions
such as ‘adult attention deficit syndrome,’ ‘erectile
dysfunction,’ and ‘premenstrual dysphoric disorder.’
This strategy is called ‘the art of disease branding’
(41). Shyness is presented as social anxiety and
menopause as a hormonal deficiency, so they also
turn into conditions to be treated by medication; new
markets can thus be created. Unjustified concerns
about high cholesterol levels are generated. The
upper cholesterol level, which was accepted to be 260
mg/dL as of 20 years ago, has now been revised down
to 200 mg/dL. Another similar situation is seen with
arterial tension levels. Are these modifications really
based on pure medical reasons, or should we have
doubts?
The answer may be hidden in sales figures. The
acceptability ranges of such medical parameters are
determined by the National Institute of Health (NIH)

in the US. When the normal cholesterol levels were
lowered by the NIH in 2001, the number of people to
use cholesterol-lowering drugs immediately tripled
(41). Sales consequently soared; particularly Mevacor,
which was introduced in 1987, and Lipitor are among
the most prescribed medicines ever (41). In 2004,
the NIH, having first advocated direct relationships
of its employees with drug companies, which it
then regarded as innocuous, issued a circular to its
scientific staff following serious criticism, requiring
that the connections with the pharmaceutics sector
be severed (41). Nevertheless, it has been a long time
since bone density or cholesterol figures became an
obsession for some.
The most striking example of an invented disease
is probably the Sisi syndrome; it emerged in 1998
with a single-page announcement from a drug firm.
The disease, allegedly a special kind of depression,
was first meant to be named after Princess Diana;
however, the melodious nickname ‘Sisi,’ from the
name of the Austrian Empress Elisabeth, was later
found to be more convenient. Thus, people were
granted the privilege of having a noble disease (42).
The fact that the Sisi syndrome was neither known
nor observed in non-German-speaking countries
must indicate that it was reserved for Germanic
nobility only. After a while, it was revealed that the
disease was made up.
Indeed, all of these new strategies highlight a
change in goals; medicine is heading toward the
healthy rich instead of poor patients and treatments
have been commercialized. The diet and slimming
formulas mentioned above are a part of those tactics.
It has become so usual to pronounce the word
‘money’ in the treatment process that some new
schemes are suggested to reward patients with money
instead of charging them bills, thus going beyond
what is ‘traditional.’ In this context, the results of
a study published in the Journal of the American
Medical Association demonstrated that obese people
who were offered financial incentives for losing
weight were approximately 5 times more successful
than those expecting no prize. While 10.5% of the
control group with no incentive achieved the weightloss goal of 7.20 kg, the rate was 52.6% and 47.4%,
respectively, for the other 2 groups that did receive
money (43). The research states that weight loss
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increases depending on the incentives offered, and
that the observed weight loss was, however, not fully
sustained; further work is needed to validate this
approach (43).
As their weight continues to increase in contrast
with the incessant insistence that it be lowered,
modern humans in a materialistic popular culture
seem to have adopted financial prerequisites to invest
in their own health, as well.
Conclusion
It is uncontroversial to say that overweight causes
disease, and the global dimension that the issue of
obesity has reached is visible to the eye. In this article,
several forms of exploitation and merchandising
in the wake of this epidemic were discussed. Such
intentions violate the medical ethical principle of
doing no harm and deprive people of true treatment.
Today, we have no objections if a dozen different
drugs are developed for treating any newly described
disease. The profit strategies of some entities in the
health sector are negligent of human responsibility

and the media is shaping public perception through
the models it imposes. In addition to unhealthy
eating habits, these mechanisms infuse society with
deleterious requirements of manufactured fads;
irrespective of the potentially harmful effects, they
choose to drive the masses to seek remedies in new
markets.
An essential step toward the solution of this
dilemma is to constitute a self-control mechanism in
medicine to render approaches to healthcare more
rational and humane; the most effective way to obviate
the exploitation is to reemphasize the authority of
conventional medicine. The disinformation generated
through mass media by people with no particular
qualification, providing herbal prescriptions and
giving general advice, should be prevented.
The overweight problem, an issue that belongs
to medicine, is diverted into external and irrelevant
fields. Like every health problem, this matter, too,
should be restored to the seriousness it deserves and
be treated from a perspective with the human at the
center.
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